The new Moderna COVID vaccine, mNexspike, is approved for adults 65 and older and people 12 to 64 with an underlying medical ...

Moderna is down 35.3% since the beginning of the year, and at $27.16 per share, it is trading 50.3% below its 52-week high of ...

Cardiologists need to know how to recognize and manage the cardiac effects that can arise from SARS-CoV-2 infections or COVID ...

ATLANTA — Moderna’s respiratory syncytial virus vaccine is safe and effective for adults who have received a solid organ ...

Mixed options sentiment in Moderna (MRNA), with shares down 2c near $26.73. Options volume relatively light with 20k contracts traded and calls ...

It’s no secret that our bodies’ ability to ward off pathogens and mount strong vaccine responses weakens with age, but ...

Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus vaccine candidate, mRNA-1647.

Shares of Moderna (MRNA) are up $1.97, or 8% to $26.67 in morning trading. Published first on TheFly – the ultimate source for real-time, ...

Welcome to the Fierce Biotech Graveyard, a yearly ritual where we remember all the biotechs we lost in 2025. While we're ...

In this week’s edition of InnovationRx, we look Nvidia’s collaborations in life sciences and drug development, Cobot’s ...

Baron Health Care Fund gained for the quarter and outperformed its benchmark, the Russell 3000 Health Care Index. Read more ...

Moderna was the only company to participate in the public procurement tender for Covid-19 vaccines, meaning that Hungarian can once again be vaccinated against coronavirus with Moderna vaccines during ...